Symbols / TNYA
TNYA Chart
About
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 132.39M |
| Enterprise Value | 57.03M | Income | -94.26M | Sales | — |
| Book/sh | 0.51 | Cash/sh | 0.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | 97 | IPO | — |
| P/E | — | Forward P/E | -1.32 | PEG | — |
| P/S | — | P/B | 1.21 | P/C | — |
| EV/EBITDA | -0.64 | EV/Sales | — | Quick Ratio | 4.26 |
| Current Ratio | 4.64 | Debt/Eq | 13.91 | LT Debt/Eq | — |
| EPS (ttm) | -0.75 | EPS next Y | -0.46 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -49.48% |
| ROE | -96.44% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 216.51M |
| Shs Float | 124.03M | Short Float | 22.10% | Short Ratio | 7.16 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.36 |
| Beta | 3.19 | Avg Volume | 4.88M | Volume | 3.51M |
| Target Price | $10.00 | Recom | None | Prev Close | $0.59 |
| Price | $0.61 | Change | 4.19% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$0.61
Latest analyst target
3. DCF / Fair value
$-3.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.61
Low
$2.00
High
$40.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-18 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-12-12 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-11-10 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-07 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-04-25 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | main | Canaccord Genuity | Buy → Buy | $6 |
| 2025-03-12 | main | Morgan Stanley | Overweight → Overweight | $5 |
| 2025-03-12 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-03-11 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-18 | main | Chardan Capital | Buy → Buy | $18 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- Major Tenaya Therapeutics Shareholder Makes Bold Move With Large Stock Sale - TipRanks Wed, 25 Feb 2026 02
- $TNYA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed - Yahoo Finance Sun, 14 Dec 2025 08
- Nasdaq bid-price warning hits Tenaya Therapeutics (Nasdaq: TNYA) as equity inducement pool grows - Stock Titan Fri, 30 Jan 2026 08
- Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 - Finviz Mon, 19 Jan 2026 08
- Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise - simplywall.st hu, 22 Jan 2026 08
- Tenaya Therapeutics (TNYA) Price Target Lowered by HC Wainwright & Co. | TNYA Stock News - GuruFocus Fri, 12 Dec 2025 08
- Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech - Yahoo Finance Mon, 12 Jan 2026 08
- Gene therapy trials for inherited heart disease face big 2026 tests - Stock Titan Fri, 09 Jan 2026 08
- Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance hu, 20 Nov 2025 08
- Tenaya Therapeutics (Nasdaq: TNYA) proposes unit offering of common stock and warrants - Stock Titan hu, 11 Dec 2025 08
- Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway - Yahoo Finance Fri, 23 Jan 2026 08
- Tenaya Therapeutics Stock (TNYA) Opinions on CEO Conference Appearances - Quiver Quantitative Fri, 10 Oct 2025 07
- Tenaya (NASDAQ: TNYA) presents TN-201 MyPEAK-1 interim data in AHA late-breaking session - Stock Titan ue, 04 Nov 2025 08
- $TNYA stock is up 4% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14862 | 9557 | — | Sale at price 0.64 per share. | ALI FARAZ | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 5160 | 3319 | — | Sale at price 0.64 per share. | TINGLEY WHITTEMORE PH.D., M.D. | Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 3469 | 2231 | — | Sale at price 0.64 per share. | HIGA TOMOHIRO | Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 4400290 | 3042222 | — | Sale at price 0.68 - 0.82 per share. | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-11 00:00:00 | I |
| 4 | 158600 | — | — | Stock Award(Grant) at price 0.00 per share. | ALI FARAZ | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 48750 | — | — | Stock Award(Grant) at price 0.00 per share. | TINGLEY WHITTEMORE PH.D., M.D. | Officer | — | 2026-02-03 00:00:00 | D |
| 6 | 29250 | — | — | Stock Award(Grant) at price 0.00 per share. | HIGA TOMOHIRO | Officer | — | 2026-02-03 00:00:00 | D |
| 7 | 3126 | 4158 | — | Sale at price 1.33 per share. | ALI FARAZ | Chief Executive Officer | — | 2025-11-17 00:00:00 | D |
| 8 | 2877 | 3826 | — | Sale at price 1.33 per share. | TINGLEY WHITTEMORE PH.D., M.D. | Officer | — | 2025-11-17 00:00:00 | D |
| 9 | 1367 | 1818 | — | Sale at price 1.33 per share. | HIGA TOMOHIRO | Officer | — | 2025-11-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -107.48M | -122.51M | -119.15M | -69.84M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -111.13M | -124.08M | -123.67M | -72.72M |
| ReconciledDepreciation | 8.47M | 8.69M | 6.47M | 2.96M |
| EBITDA | -107.48M | -122.51M | -119.15M | -69.84M |
| EBIT | -115.95M | -131.19M | -125.62M | -72.81M |
| NetInterestIncome | 4.74M | 7.06M | 1.95M | 108.00K |
| InterestIncome | 4.74M | 7.06M | 1.95M | 108.00K |
| NormalizedIncome | -111.13M | -124.08M | -123.67M | -72.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -111.13M | -124.08M | -123.67M | -72.72M |
| TotalExpenses | 115.95M | 131.19M | 125.62M | 72.81M |
| TotalOperatingIncomeAsReported | -115.95M | -131.19M | -125.62M | -72.81M |
| DilutedAverageShares | 84.82M | 73.79M | 44.82M | 17.73M |
| BasicAverageShares | 84.82M | 73.79M | 44.82M | 17.73M |
| DilutedEPS | -1.31 | -1.68 | -2.76 | -4.10 |
| BasicEPS | -1.31 | -1.68 | -2.76 | -4.10 |
| DilutedNIAvailtoComStockholders | -111.13M | -124.08M | -123.67M | -72.72M |
| NetIncomeCommonStockholders | -111.13M | -124.08M | -123.67M | -72.72M |
| NetIncome | -111.13M | -124.08M | -123.67M | -72.72M |
| NetIncomeIncludingNoncontrollingInterests | -111.13M | -124.08M | -123.67M | -72.72M |
| NetIncomeContinuousOperations | -111.13M | -124.08M | -123.67M | -72.72M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -111.13M | -124.08M | -123.67M | -72.72M |
| OtherIncomeExpense | 82.00K | 53.00K | 2.00K | -23.00K |
| OtherNonOperatingIncomeExpenses | 82.00K | 53.00K | 2.00K | -23.00K |
| NetNonOperatingInterestIncomeExpense | 4.74M | 7.06M | 1.95M | 108.00K |
| InterestIncomeNonOperating | 4.74M | 7.06M | 1.95M | 108.00K |
| OperatingIncome | -115.95M | -131.19M | -125.62M | -72.81M |
| OperatingExpense | 115.95M | 131.19M | 125.62M | 72.81M |
| ResearchAndDevelopment | 86.74M | 98.04M | 94.54M | 54.39M |
| SellingGeneralAndAdministration | 29.21M | 33.16M | 31.08M | 18.41M |
| GeneralAndAdministrativeExpense | 29.21M | 33.16M | 31.08M | 18.41M |
| OtherGandA | 29.21M | 33.16M | 31.08M | 18.41M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 86.54M | 68.33M | 66.86M | 41.29M |
| ShareIssued | 86.54M | 68.33M | 66.86M | 41.29M |
| TotalDebt | 13.61M | 12.42M | 15.10M | 15.70M |
| TangibleBookValue | 92.85M | 139.42M | 243.38M | 278.53M |
| InvestedCapital | 92.85M | 139.42M | 243.38M | 278.53M |
| WorkingCapital | 51.40M | 88.85M | 169.51M | 233.58M |
| NetTangibleAssets | 92.85M | 139.42M | 243.38M | 278.53M |
| CapitalLeaseObligations | 13.61M | 12.42M | 15.10M | 15.70M |
| CommonStockEquity | 92.85M | 139.42M | 243.38M | 278.53M |
| TotalCapitalization | 92.85M | 139.42M | 243.38M | 278.53M |
| TotalEquityGrossMinorityInterest | 92.85M | 139.42M | 243.38M | 278.53M |
| StockholdersEquity | 92.85M | 139.42M | 243.38M | 278.53M |
| GainsLossesNotAffectingRetainedEarnings | 28.00K | -106.00K | -378.00K | -141.00K |
| OtherEquityAdjustments | 28.00K | -106.00K | -378.00K | -141.00K |
| RetainedEarnings | -514.41M | -403.28M | -279.20M | -155.53M |
| AdditionalPaidInCapital | 607.23M | 542.80M | 522.95M | 434.20M |
| CapitalStock | 8.00K | 7.00K | 7.00K | 4.00K |
| CommonStock | 8.00K | 7.00K | 7.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 27.09M | 31.09M | 35.57M | 35.66M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 11.11M | 8.36M | 11.32M | 13.89M |
| OtherNonCurrentLiabilities | 281.00K | 253.00K | 228.00K | 182.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 10.83M | 8.11M | 11.09M | 13.71M |
| LongTermCapitalLeaseObligation | 10.83M | 8.11M | 11.09M | 13.71M |
| CurrentLiabilities | 15.97M | 22.73M | 24.25M | 21.77M |
| OtherCurrentLiabilities | 214.00K | 478.00K | 545.00K | 162.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 2.78M | 4.32M | 4.01M | 1.99M |
| CurrentCapitalLeaseObligation | 2.78M | 4.32M | 4.01M | 1.99M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.59M | 8.70M | 6.42M | 3.67M |
| PayablesAndAccruedExpenses | 7.39M | 9.24M | 13.27M | 15.95M |
| CurrentAccruedExpenses | 1.88M | 3.33M | 3.70M | 5.23M |
| Payables | 5.51M | 5.91M | 9.58M | 10.72M |
| TotalTaxPayable | 348.00K | 280.00K | ||
| AccountsPayable | 5.16M | 5.63M | 9.58M | 10.72M |
| TotalAssets | 119.94M | 170.51M | 278.94M | 314.19M |
| TotalNonCurrentAssets | 52.56M | 58.93M | 85.19M | 58.83M |
| OtherNonCurrentAssets | 4.82M | 5.68M | 4.79M | 4.13M |
| InvestmentsAndAdvances | 0.00 | 17.70M | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | 17.70M | 0.00 | |
| AvailableForSaleSecurities | 17.70M | |||
| NetPPE | 47.75M | 53.26M | 62.70M | 54.70M |
| AccumulatedDepreciation | -32.29M | -24.34M | -15.68M | -9.43M |
| GrossPPE | 80.04M | 77.60M | 78.37M | 64.13M |
| Leases | 26.16M | 25.61M | 23.61M | 7.24M |
| ConstructionInProgress | 1.92M | 1.73M | 3.13M | 32.56M |
| OtherProperties | 31.66M | 29.95M | 32.20M | 23.58M |
| MachineryFurnitureEquipment | 20.30M | 20.31M | 19.44M | 752.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 67.38M | 111.58M | 193.75M | 255.36M |
| OtherCurrentAssets | 842.00K | 1.16M | 938.00K | 4.06M |
| PrepaidAssets | 5.09M | 5.78M | 4.04M | 4.06M |
| Receivables | 0.00 | 2.25M | ||
| TaxesReceivable | 0.00 | 2.25M | ||
| CashCashEquivalentsAndShortTermInvestments | 61.45M | 104.64M | 186.53M | 251.30M |
| OtherShortTermInvestments | 57.12M | 58.96M | 91.25M | 213.17M |
| CashAndCashEquivalents | 4.32M | 45.68M | 95.27M | 38.13M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -91.53M | -103.31M | -125.05M | -85.93M |
| RepurchaseOfCapitalStock | 0.00 | -13.00K | ||
| IssuanceOfCapitalStock | 46.76M | 3.87M | 77.39M | 208.52M |
| CapitalExpenditure | -1.02M | -1.24M | -20.63M | -25.12M |
| EndCashPosition | 4.74M | 46.36M | 95.67M | 38.68M |
| BeginningCashPosition | 46.36M | 95.67M | 38.68M | 129.08M |
| ChangesInCash | -41.62M | -49.31M | 56.99M | -90.41M |
| FinancingCashFlow | 47.75M | 4.05M | 77.77M | 208.97M |
| CashFlowFromContinuingFinancingActivities | 47.75M | 4.05M | 77.77M | 208.97M |
| NetOtherFinancingCharges | -501.00K | 87.00K | ||
| ProceedsFromStockOptionExercised | 987.00K | 682.00K | 380.00K | 374.00K |
| NetPreferredStockIssuance | 0.00 | 19.98M | ||
| PreferredStockIssuance | 0.00 | 19.98M | ||
| NetCommonStockIssuance | 46.76M | 3.87M | 77.39M | 188.53M |
| CommonStockPayments | 0.00 | -13.00K | ||
| CommonStockIssuance | 46.76M | 3.87M | 77.39M | 188.54M |
| InvestingCashFlow | 1.13M | 48.72M | 83.65M | -238.56M |
| CashFlowFromContinuingInvestingActivities | 1.13M | 48.72M | 83.65M | -238.56M |
| NetOtherInvestingChanges | 17.00K | -25.00K | 8.00K | |
| NetInvestmentPurchaseAndSale | 2.14M | 49.98M | 104.27M | -213.44M |
| SaleOfInvestment | 89.21M | 106.62M | 244.75M | 0.00 |
| PurchaseOfInvestment | -87.07M | -56.64M | -140.48M | -213.44M |
| NetPPEPurchaseAndSale | -1.02M | -1.24M | -20.63M | -25.12M |
| PurchaseOfPPE | -1.02M | -1.24M | -20.63M | -25.12M |
| OperatingCashFlow | -90.50M | -102.07M | -104.42M | -60.81M |
| CashFlowFromContinuingOperatingActivities | -90.50M | -102.07M | -104.42M | -60.81M |
| ChangeInWorkingCapital | -7.93M | -5.65M | -849.00K | 4.74M |
| ChangeInOtherCurrentLiabilities | -4.12M | -4.12M | -3.11M | -1.31M |
| ChangeInOtherCurrentAssets | 656.00K | -601.00K | -815.00K | -3.11M |
| ChangeInPayablesAndAccruedExpense | -5.33M | -1.03M | 6.01M | 11.89M |
| ChangeInAccruedExpense | -4.75M | 2.26M | 4.35M | 3.29M |
| ChangeInPayable | -581.00K | -3.28M | 1.66M | 8.60M |
| ChangeInAccountPayable | -581.00K | -3.28M | 1.66M | 8.60M |
| ChangeInPrepaidAssets | 857.00K | 101.00K | -2.93M | -2.73M |
| OtherNonCashItems | 3.77M | 3.35M | 2.46M | 1.12M |
| StockBasedCompensation | 16.50M | 15.31M | 11.47M | 2.95M |
| AmortizationOfSecurities | -184.00K | 315.00K | -307.00K | 131.00K |
| DepreciationAmortizationDepletion | 8.47M | 8.69M | 6.47M | 2.96M |
| DepreciationAndAmortization | 8.47M | 8.69M | 6.47M | 2.96M |
| Depreciation | 8.47M | 8.69M | 6.47M | |
| OperatingGainsLosses | 61.00K | |||
| GainLossOnSaleOfPPE | 61.00K | |||
| NetIncomeFromContinuingOperations | -111.13M | -124.08M | -123.67M | -72.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TNYA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|